Bionik Laboratories Corp. (BNKL) SEC Filing 8-K Material Event for the period ending Monday, October 22, 2018

Bionik Laboratories Corp.

CIK: 1508381 Ticker: BNKL

View differences made from one to another to evaluate Bionik Laboratories Corp.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bionik Laboratories Corp..


Assess how Bionik Laboratories Corp.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bionik Laboratories Corp.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Bionik Laboratories Corp. provided additional information to their SEC Filing as exhibits

Ticker: BNKL
CIK: 1508381
Form Type: 8-K Corporate News
Accession Number: 0001144204-18-055058
Submitted to the SEC: Wed Oct 24 2018 8:00:54 AM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Monday, October 22, 2018
Industry: Orthopedic Prosthetic And Surgical Appliances And Supplies
  1. Event for Officers
  2. Financial Exhibit
  3. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: